Related Experiment Video
Updated: Sep 3, 2025
08:57
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
2.1K
Case Report: Paraneoplastic Tumefactive Demyelination Associated With Seminoma
Wataru Shiraishi1,2, Takeru Umemura3, Yuuki Nakayama4
1Department of Neurology, Kokura Memorial Hospital, Kitakyushu, Japan.
Frontiers in Neurology
|July 28, 2022
Summary
This case study details a rare instance of paraneoplastic tumefactive demyelination linked to testicular seminoma, potentially triggered by COVID-19 vaccination. Early recognition of this neurological syndrome is crucial for patient management.
Area of Science:
- Neuroimmunology
- Neuropathology
- Oncology
Background:
- Paraneoplastic tumefactive demyelination (TD) is a rare central nervous system disorder.
- Diagnosis can be challenging, especially when presenting as a paraneoplastic neurological syndrome.
Observation:
- A 32-year-old man presented with neurological deficits post-COVID-19 vaccination.
- He had a history of testicular enlargement and elevated tumor markers, later diagnosed as seminoma.
- Brain MRI revealed a demyelinating lesion that progressed despite initial treatment.
Findings:
- The patient was diagnosed with tumefactive demyelination associated with testicular seminoma.
- Anti-amphiphysin antibodies were detected.
- Initial steroid therapy was ineffective; gamma globulin therapy showed partial improvement alongside chemotherapy.
Implications:
- This case highlights the importance of considering paraneoplastic TD in patients with unexplained neurological symptoms.
- The potential association with COVID-19 vaccination warrants further investigation.
- Recognizing this rare syndrome is critical for timely diagnosis and management.
